Secorapamycin A is primarily investigated for its potential therapeutic applications, particularly in the field of cancer research. It is known to exhibit immunosuppressive and antiproliferative properties, making it a candidate for use in targeted cancer therapies. The compound is studied for its ability to inhibit mTOR (mechanistic target of rapamycin) signaling pathways, which play a critical role in cell growth and proliferation. By disrupting these pathways, Secorapamycin A may help in controlling the growth of certain types of tumors. Additionally, its immunosuppressive effects are being explored for use in organ transplantation to prevent graft rejection. Research is ongoing to further understand its efficacy, safety, and potential applications in medical treatments.